Cumulative Gains Are Building Blocks to Incredible Progress in War Against Cancer

Washington, D.C. (June 12, 2012) — Following Food and Drug Administration (FDA) approval of a new cancer medicine, it often takes years of additional research to fully understand the value of the medicine to patients, according to "Recognizing Value in Oncology Innovation," a new paper released by the Boston Healthcare Associates (BHA).

Recognizing Value in Oncology Innovation Report

Recognizing Value In Oncology Innovation Executive Summary

Nearly 1,000 Medicines in Development to Help Patients in Their Fight Against Cancer

PhRMA Urges President Obama to Secure an Ambitious Trans-Pacific Partnership Agreement

Washington, D.C. (May 8, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today:

“PhRMA joins with a large group of U.S trade associations urging President Obama to complete his vision for a strong, ambitious Trans-Pacific Partnership Agreement (TPP) which would further economic growth by strengthening American trade with the Asia-Pacific region.

PhRMA Statement on Special 301 Report

Washington, D.C. (May 2, 2012) — The Pharmaceutical Research and Manufacturers of America (PhRMA) released the following statement today on the Special 301 Report issued by the United States Trade Representative (USTR).

Medicines in Development for Vaccines

Washington, D.C. (April 20, 2012)— America’s biopharmaceutical research companies are developing nearly 300 vaccines for the prevention and treatment of a wide variety of diseases, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The vaccines – all either currently tested in clinical trials or under review by the Food and Drug Administration – include 170 for infectious diseases, 102 for cancers and eight for neurological disorders.

PhRMA Statement Regarding Research Partnerships and Clinical Trials

Washington, D.C. (April 12, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement today:

“Today, two important reports were released that together paint a vivid picture of the role of collaboration in the research ecosystem – one by highlighting partnerships with academic medical centers (AMCs) and one by highlighting the contributions patients make to medical research by participating in clinical trials.

PhRMA: Compulsory Licensing in India

Washington, D.C. (March 13, 2012) — PhRMA President and CEO John Castellani issued the following statement today, on India issuing a compulsory license:

“The research based pharmaceutical industry believes that all people around the world should have access to quality healthcare and lifesaving medicines. In partnership with other stakeholders, the industry is committed to playing a full part in addressing the healthcare challenges of the developing world by taking an innovative, responsible, and, above all, sustainable approach.

PhRMA Statement on Human Brain Mapping Initiative

WASHINGTON, D.C. (February 18, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today regarding a new initiative by the Administration that could help further medical research for neurological diseases:


Subscribe to RSS - Innovation